Dr. Nir Peled is an Israeli oncologist and was a Fulbright Scholar at the University of Colorado Cancer Center.
While on his grant he conducted a study focusing on early detection of lung cancer by exhale breath analysis. As part of his research, he is developing a "cancer sniffer" - a device that samples the breath of lung cancer patients before and after definitive therapy and analyzes the breath sample for a volatile organic compound that is a biomarker for lung cancer.
This groundbreaking apparatus will also serve as an early detector for other forms of cancer, including breast and colon cancers. CU and the Israel Institute of Technology, Technion, in Haifa, Israel, which developed the technology, expect that the device will hit the market in about four years, but its potential to save lives is already evident.
Dr. Peled's Fulbright grant has already impacted his academic career with the opportunity to write two review papers and collaborate on three book chapters about lung cancer with colleagues from CU.
"My Fulbright post-doctoral research at the University of Colorado Cancer Center is already one of the strongest experiences I have had in my career," Dr. Peled says. He returned to Israel at the conclusion of his grant and plans to lead a research team focusing on translational research.
Related Links:
Denver Post article